Evidence Hub

Systematic evaluation and meta-analysis of the efficacy and tolerability of tegoprazan in an Asian population

Yifan Chen, Yi Chen, Tongxi Li, Yonglang Cheng, Zhiwei Huang, Tianying Cai, Junjie Bai, Ziming Wu et al.

2022

Abstract

Review question / Objective: P (Population): Diabetic patients and healthy subjects. I (Intervention): Different doses of dasiglucagon. C (Comparison): Placebo. O (Outcome) : The primary outcome was the median time to recovery of plasma glucose (PG) (first PG increase of ≥20 mg/dL from the baseline after treatment initiation). The number of occurrences in which PG initially increased by ≥20 mg/dL from the baseline within 10, 15, 20, and 30 minutes was one of the secondary outcomes. The median time to reach a PG level of ≥70 mg/dL was another secondary outcome. The aforementioned outcomes were established without the use of intravenous rescue glucose. S (Study design) : The data in this study were obtained from randomized controlled trials.

How strong is the evidence?

Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free